Gestational age determination and prevention of HIV perinatal transmission
- 23 November 2005
- journal article
- research article
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 92 (2) , 176-180
- https://doi.org/10.1016/j.ijgo.2005.09.021
Abstract
To compare different methods of gestational age (GA) measurement for ensuring effective zidovudine (ZDV) prophylaxis to prevent mother-to-child transmission of HIV.For 1398 HIV-infected women enrolled in a perinatal prevention trial, gestation durations were calculated based on GA estimated using ultrasound (US), date of last menstruation period (LMP), first fundal height (FH(1)), and a specific algorithm was developed to provide a "reference" GA. The performance of each GA estimate was evaluated by the percentage of women who would have received > or =8 weeks ZDV, if prophylaxis was initiated at 28 weeks.The performances of the algorithm, US, LMP, and FH(1) were 95.5%, 94.8%, 88.4%, and 83.7%, respectively. US and FH(1) were significantly better when estimated before and after 24 weeks, respectively.In situations where no US is available and LMP is not or imprecisely known, FH(1) can be used after 24 weeks to schedule ZDV initiation date.Keywords
This publication has 6 references indexed in Scilit:
- Algorithms for combining menstrual and ultrasound estimates of gestational age: consequences for rates of preterm and postterm birthBJOG: An International Journal of Obstetrics and Gynaecology, 2002
- Combination antiretroviral therapy and duration of pregnancyAIDS, 2000
- A Trial of Shortened Zidovudine Regimens to Prevent Mother-to-Child Transmission of Human Immunodeficiency Virus Type 1New England Journal of Medicine, 2000
- Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trialThe Lancet, 1999
- Is zidovudine therapy in pregnant HIV-infected women associated with gestational age and birthweight?AIDS, 1999
- Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine TreatmentNew England Journal of Medicine, 1994